Arshad Ali
@aldorenin.bsky.social
Nephrologist FACP FASN | In love with Medicine | MKSAP-Reviewer Renal-physiology| EmoryNephrology | MorehouseMedicine | Love & hate Politics| Faith+Optimism🇺🇸
Reposted by Arshad Ali
The December 2025 issue is available now: bit.ly/43SrjDd
Highlights:
- Intronic and Coding Genetic Variants in Autosomal Recessive Polycystic Kidney Disease Among Israeli Bedouins of Arabian Peninsula Ancestry
- Nephrologist Perspectives on Using Telemedicine During In-Center Hemodialysis
Highlights:
- Intronic and Coding Genetic Variants in Autosomal Recessive Polycystic Kidney Disease Among Israeli Bedouins of Arabian Peninsula Ancestry
- Nephrologist Perspectives on Using Telemedicine During In-Center Hemodialysis
November 26, 2025 at 11:00 AM
The December 2025 issue is available now: bit.ly/43SrjDd
Highlights:
- Intronic and Coding Genetic Variants in Autosomal Recessive Polycystic Kidney Disease Among Israeli Bedouins of Arabian Peninsula Ancestry
- Nephrologist Perspectives on Using Telemedicine During In-Center Hemodialysis
Highlights:
- Intronic and Coding Genetic Variants in Autosomal Recessive Polycystic Kidney Disease Among Israeli Bedouins of Arabian Peninsula Ancestry
- Nephrologist Perspectives on Using Telemedicine During In-Center Hemodialysis
Reposted by Arshad Ali
T0j: #NephJC
The ORIGIN phase 2b trial
👥 116 patients with biopsy-proven IgAN and persistent proteinuria despite RASi
💉 Weekly atacicept 150 mg (wk 36)
⬆️ 35% greater UPCR reduction vs placebo
⚙️ a mean eGFR benefit of +5.8 mL/min/1.73 m²
pubmed.ncbi.nlm.nih....
The ORIGIN phase 2b trial
👥 116 patients with biopsy-proven IgAN and persistent proteinuria despite RASi
💉 Weekly atacicept 150 mg (wk 36)
⬆️ 35% greater UPCR reduction vs placebo
⚙️ a mean eGFR benefit of +5.8 mL/min/1.73 m²
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:18 AM
T0j: #NephJC
The ORIGIN phase 2b trial
👥 116 patients with biopsy-proven IgAN and persistent proteinuria despite RASi
💉 Weekly atacicept 150 mg (wk 36)
⬆️ 35% greater UPCR reduction vs placebo
⚙️ a mean eGFR benefit of +5.8 mL/min/1.73 m²
pubmed.ncbi.nlm.nih....
The ORIGIN phase 2b trial
👥 116 patients with biopsy-proven IgAN and persistent proteinuria despite RASi
💉 Weekly atacicept 150 mg (wk 36)
⬆️ 35% greater UPCR reduction vs placebo
⚙️ a mean eGFR benefit of +5.8 mL/min/1.73 m²
pubmed.ncbi.nlm.nih....
Reposted by Arshad Ali
T0f: #NephJC
1️⃣In IgAN, mucosal dendritic cells activate Tfh cells and directly drive B‑cell class switching via BAFF and APRIL, generating pathogenic IgA ☠️
2️⃣The expansion and mis‑trafficking of Gd‑IgA1+ B cells 👉 excess circulating Gd‑IgA1
pubmed.ncbi.nlm.nih....
1️⃣In IgAN, mucosal dendritic cells activate Tfh cells and directly drive B‑cell class switching via BAFF and APRIL, generating pathogenic IgA ☠️
2️⃣The expansion and mis‑trafficking of Gd‑IgA1+ B cells 👉 excess circulating Gd‑IgA1
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:13 AM
T0f: #NephJC
1️⃣In IgAN, mucosal dendritic cells activate Tfh cells and directly drive B‑cell class switching via BAFF and APRIL, generating pathogenic IgA ☠️
2️⃣The expansion and mis‑trafficking of Gd‑IgA1+ B cells 👉 excess circulating Gd‑IgA1
pubmed.ncbi.nlm.nih....
1️⃣In IgAN, mucosal dendritic cells activate Tfh cells and directly drive B‑cell class switching via BAFF and APRIL, generating pathogenic IgA ☠️
2️⃣The expansion and mis‑trafficking of Gd‑IgA1+ B cells 👉 excess circulating Gd‑IgA1
pubmed.ncbi.nlm.nih....
Reposted by Arshad Ali
#NephJC It’s Tuesday I’m in love?!
a group of men standing in front of the words the cure
ALT: a group of men standing in front of the words the cure
media.tenor.com
November 19, 2025 at 2:11 AM
#NephJC It’s Tuesday I’m in love?!
Reposted by Arshad Ali
T0c: #NephJC
First, the guideline seems outdated. Until now, we aimed to slow CKD progression 🐌, but what if we look from a more daring perspective? Like oncologists/ rheum…
With armamentarium we have now, we can aim for remission 🛑, dare I say “cure”?
pubmed.ncbi.nlm.nih....
First, the guideline seems outdated. Until now, we aimed to slow CKD progression 🐌, but what if we look from a more daring perspective? Like oncologists/ rheum…
With armamentarium we have now, we can aim for remission 🛑, dare I say “cure”?
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:10 AM
T0c: #NephJC
First, the guideline seems outdated. Until now, we aimed to slow CKD progression 🐌, but what if we look from a more daring perspective? Like oncologists/ rheum…
With armamentarium we have now, we can aim for remission 🛑, dare I say “cure”?
pubmed.ncbi.nlm.nih....
First, the guideline seems outdated. Until now, we aimed to slow CKD progression 🐌, but what if we look from a more daring perspective? Like oncologists/ rheum…
With armamentarium we have now, we can aim for remission 🛑, dare I say “cure”?
pubmed.ncbi.nlm.nih....
Reposted by Arshad Ali
✍️Check the insightful #NephJC summary by @notjustdialysis.bsky.social
Attacking the Origin of IgAN: ORIGIN3 and Atacicept — NephJC
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an
APRIL/BAFF inhibitor for use in IgAN.
www.nephjc.com
November 19, 2025 at 2:04 AM
✍️Check the insightful #NephJC summary by @notjustdialysis.bsky.social
November 19, 2025 at 2:05 AM
Reposted by Arshad Ali
Mouse Alport podocytes are susceptible to AAV9 transduction in vivo
doi.org/10.1016/j.kint.2025.09.027
#MedSky #NephSky
@jeffminerphd.bsky.social @washunephrology.bsky.social @washumedicine.bsky.social
doi.org/10.1016/j.kint.2025.09.027
#MedSky #NephSky
@jeffminerphd.bsky.social @washunephrology.bsky.social @washumedicine.bsky.social
November 4, 2025 at 6:05 PM
Mouse Alport podocytes are susceptible to AAV9 transduction in vivo
doi.org/10.1016/j.kint.2025.09.027
#MedSky #NephSky
@jeffminerphd.bsky.social @washunephrology.bsky.social @washumedicine.bsky.social
doi.org/10.1016/j.kint.2025.09.027
#MedSky #NephSky
@jeffminerphd.bsky.social @washunephrology.bsky.social @washumedicine.bsky.social
Reposted by Arshad Ali
EDITORIAL by Pascale Khairallah, Elizabeth Lorenz, and Puneet Sood:
Rethinking Transplant Care Through a Sex- and Gender-Based Lens
bit.ly/433XPly (FREE)
Rethinking Transplant Care Through a Sex- and Gender-Based Lens
bit.ly/433XPly (FREE)
November 2, 2025 at 11:00 PM
EDITORIAL by Pascale Khairallah, Elizabeth Lorenz, and Puneet Sood:
Rethinking Transplant Care Through a Sex- and Gender-Based Lens
bit.ly/433XPly (FREE)
Rethinking Transplant Care Through a Sex- and Gender-Based Lens
bit.ly/433XPly (FREE)
Reposted by Arshad Ali
Freely Filtered dives into ACHIEVE with Mike Walsh. This was a great episode. Also with show notes, chapters, and key images (if your podcast client supports it) www.nephjc.com/freelyfilter...
November 2, 2025 at 2:01 PM
Freely Filtered dives into ACHIEVE with Mike Walsh. This was a great episode. Also with show notes, chapters, and key images (if your podcast client supports it) www.nephjc.com/freelyfilter...
Reposted by Arshad Ali
💗 Loved this episode. The puns were great, the trial story is even better! What really stood out was the resilience behind it.
✨Five tries to ACHIEVE the first grant, then 11 in total
✨Five tries to ACHIEVE the first grant, then 11 in total
We achieved pushing out the ACHIEVE podcast before #KidneyWk
@lastwalsh.bsky.social with @kidneyboy.bsky.social @medpeedskidneys.bsky.social @sophiakidney.bsky.social
www.nephjc.com/freelyfilter...
@lastwalsh.bsky.social with @kidneyboy.bsky.social @medpeedskidneys.bsky.social @sophiakidney.bsky.social
www.nephjc.com/freelyfilter...
FF 84 ACHIEVE: Spironolactone flops in dialysis — NephJC
FF 84 ACHIEVE: Spiro in dialysis….uhmm maybe no
www.nephjc.com
November 3, 2025 at 2:05 AM
💗 Loved this episode. The puns were great, the trial story is even better! What really stood out was the resilience behind it.
✨Five tries to ACHIEVE the first grant, then 11 in total
✨Five tries to ACHIEVE the first grant, then 11 in total
Reposted by Arshad Ali
T0c
There have been numerous developments in the field of transplantation that have improved outcomes and success rates. Today 95% of renal transplants are functional after 1 year, and 80% at five years. #NephJC
There have been numerous developments in the field of transplantation that have improved outcomes and success rates. Today 95% of renal transplants are functional after 1 year, and 80% at five years. #NephJC
October 1, 2025 at 1:10 AM
T0c
There have been numerous developments in the field of transplantation that have improved outcomes and success rates. Today 95% of renal transplants are functional after 1 year, and 80% at five years. #NephJC
There have been numerous developments in the field of transplantation that have improved outcomes and success rates. Today 95% of renal transplants are functional after 1 year, and 80% at five years. #NephJC
October 1, 2025 at 1:03 AM
Reposted by Arshad Ali
Reminder that primary hyperparathyroidism can be a cause of hypertension!
#HypertensionRounds
Successful treatment of resistant #hypertension with .... Evocalcet?
🔗 academic.oup.com/ajh/article-... 🔒
Successful treatment of resistant #hypertension with .... Evocalcet?
🔗 academic.oup.com/ajh/article-... 🔒
July 25, 2025 at 1:03 PM
Reminder that primary hyperparathyroidism can be a cause of hypertension!
Reposted by Arshad Ali
Urine CXCL-9, now in immune checkpoint inhibitor AIN! In @kidneyint.bsky.social
www.kidney-international.org/article/S008...
www.kidney-international.org/article/S008...
Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor-associated acute interstitial nephritis
Immune checkpoint inhibitor-associated acute interstitial nephritis presents significant
clinical challenges. There are no reliable non-invasive biomarkers and kidney biopsy
remains the gold standard ...
www.kidney-international.org
June 26, 2025 at 2:02 PM
Urine CXCL-9, now in immune checkpoint inhibitor AIN! In @kidneyint.bsky.social
www.kidney-international.org/article/S008...
www.kidney-international.org/article/S008...
Reposted by Arshad Ali
What is your leading diagnosis when seeing this interesting IgG staining pattern by IF?
#DiagnoseThis #pathology #renal #kidneypath
#DiagnoseThis #pathology #renal #kidneypath
June 16, 2025 at 1:03 PM
What is your leading diagnosis when seeing this interesting IgG staining pattern by IF?
#DiagnoseThis #pathology #renal #kidneypath
#DiagnoseThis #pathology #renal #kidneypath
Reposted by Arshad Ali
Triple drug combo now available in US - approved by FDA
Telmisartan 10
Amlodipine 1.25
Indapamide 0.625
george-medicines.com/george-medic...
#Hypertension
#Widaplik
Also in higher doses:
20/2.5/1.25 and
40/5/2.5
Telmisartan 10
Amlodipine 1.25
Indapamide 0.625
george-medicines.com/george-medic...
#Hypertension
#Widaplik
Also in higher doses:
20/2.5/1.25 and
40/5/2.5
George Medicines announces FDA approval of WIDAPLIK™ (telmisartan, amlodipine and indapamide), a new single pill combination treatment for hypertension in adults, including initial treatment
Novel, single pill, triple combination with a standard dose and two lower doses that can deliver the efficacy benefits of combination therapy, with an established safety profile and good tolerability ...
george-medicines.com
June 9, 2025 at 10:53 PM
Triple drug combo now available in US - approved by FDA
Telmisartan 10
Amlodipine 1.25
Indapamide 0.625
george-medicines.com/george-medic...
#Hypertension
#Widaplik
Also in higher doses:
20/2.5/1.25 and
40/5/2.5
Telmisartan 10
Amlodipine 1.25
Indapamide 0.625
george-medicines.com/george-medic...
#Hypertension
#Widaplik
Also in higher doses:
20/2.5/1.25 and
40/5/2.5
Reposted by Arshad Ali
Machine Perfusion in Deceased Donor Kidney Transplantation: Editorial Summary of a Cochrane Review by @samjtingle.bsky.social and Colin Hugh Wilson
bit.ly/AJKD25Tingle... (FREE)
bit.ly/AJKD25Tingle... (FREE)
May 23, 2025 at 10:02 AM
Machine Perfusion in Deceased Donor Kidney Transplantation: Editorial Summary of a Cochrane Review by @samjtingle.bsky.social and Colin Hugh Wilson
bit.ly/AJKD25Tingle... (FREE)
bit.ly/AJKD25Tingle... (FREE)
@askrenal.bsky.social
How do you manage a 70 yr old female with stable renal function with serum creatinine at 1.12 with positive heterozygous CFH complement factor H deficiency on genetic testing with urine sediment showing oval fat bodies with no proteinuria or hematuria. UPCR/ UACR negative.
How do you manage a 70 yr old female with stable renal function with serum creatinine at 1.12 with positive heterozygous CFH complement factor H deficiency on genetic testing with urine sediment showing oval fat bodies with no proteinuria or hematuria. UPCR/ UACR negative.
May 16, 2025 at 4:07 AM
@askrenal.bsky.social
How do you manage a 70 yr old female with stable renal function with serum creatinine at 1.12 with positive heterozygous CFH complement factor H deficiency on genetic testing with urine sediment showing oval fat bodies with no proteinuria or hematuria. UPCR/ UACR negative.
How do you manage a 70 yr old female with stable renal function with serum creatinine at 1.12 with positive heterozygous CFH complement factor H deficiency on genetic testing with urine sediment showing oval fat bodies with no proteinuria or hematuria. UPCR/ UACR negative.
Reposted by Arshad Ali
Suzetrigine: Is It A Safer Pain Medication For Patients With Kidney Disease?
www.renalfellow.org/2025/05/02/s...
www.renalfellow.org/2025/05/02/s...
Suzetrigine: Is It A Safer Pain Medication For Patients With Kidney Disease?
Pain management in patients with chronic kidney disease (CKD) is complex. Widely used analgesics like opioids, NSAIDs and gabapentinoids may directly or indirec
www.renalfellow.org
May 3, 2025 at 8:58 PM
Suzetrigine: Is It A Safer Pain Medication For Patients With Kidney Disease?
www.renalfellow.org/2025/05/02/s...
www.renalfellow.org/2025/05/02/s...
Reposted by Arshad Ali
Cool diagnosis in a dialysis patient
www.nytimes.com/2025/05/02/w...
@rmcentor.bsky.social in the NYT
H/t @doctorajgu.medsky.social
#NephSky
www.nytimes.com/2025/05/02/w...
@rmcentor.bsky.social in the NYT
H/t @doctorajgu.medsky.social
#NephSky
He Was Sure Dialysis Had Caused His Belly Pain. But Why?
The patient’s symptoms had sent him to the emergency room 22 times in the past year.
www.nytimes.com
May 2, 2025 at 9:55 AM
Cool diagnosis in a dialysis patient
www.nytimes.com/2025/05/02/w...
@rmcentor.bsky.social in the NYT
H/t @doctorajgu.medsky.social
#NephSky
www.nytimes.com/2025/05/02/w...
@rmcentor.bsky.social in the NYT
H/t @doctorajgu.medsky.social
#NephSky
Reposted by Arshad Ali
The ASIs have arrived
www.nejm.org/doi/full/10....
Aldosterone synthase inhibitors - first one to finish the phase 3 line
#Lorundrostat #Hypertension
www.nejm.org/doi/full/10....
Aldosterone synthase inhibitors - first one to finish the phase 3 line
#Lorundrostat #Hypertension
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension | NEJM
Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this mult...
www.nejm.org
April 23, 2025 at 10:01 PM
The ASIs have arrived
www.nejm.org/doi/full/10....
Aldosterone synthase inhibitors - first one to finish the phase 3 line
#Lorundrostat #Hypertension
www.nejm.org/doi/full/10....
Aldosterone synthase inhibitors - first one to finish the phase 3 line
#Lorundrostat #Hypertension
Reposted by Arshad Ali
#RenalPath: Malakoplakia with mass-like sheets of macrophages with granular eosinophilic cytoplasm and scattered neutrophils within the interstitium and tubules (hematoxylin and eosin stain).
bit.ly/2uaW9ba (FREE)
bit.ly/2uaW9ba (FREE)
April 20, 2025 at 10:01 AM
#RenalPath: Malakoplakia with mass-like sheets of macrophages with granular eosinophilic cytoplasm and scattered neutrophils within the interstitium and tubules (hematoxylin and eosin stain).
bit.ly/2uaW9ba (FREE)
bit.ly/2uaW9ba (FREE)
Reposted by Arshad Ali
March 23, 2025 at 5:03 PM